MGRXNasdaqServices-Misc Health & Allied Services, NECUS GAAP · USD

Mangoceuticals, Inc

Mangoceuticals, Inc. operates a telemedicine and e-commerce-style healthcare platform focused on men’s wellness. Through MangoRx.com, it connects consumers with licensed healthcare professionals and markets prescription-based products for erectile dysfunction, hair loss, hormone support, and weight management, including compounded products and the FDA-approved PRIME testosterone therapy offering.

Ask about the company
Revenue0.5m USD
−26.0 %y/y
Operating profit (EBIT)-18.0m USD
−126.2 %y/y
EBIT margin-3,954.3%
−2,659.9 ppy/y
Net income-20.6m USD
−137.1 %y/y

Fiscal year 2025 · change from previous year

Development 2022–2025

-20-15-10-505m USD2022: 0.01 m USD2022: EBIT -2.0 m USD20222023: 0.73 m USD2023: EBIT -9.2 m USD20232024: 0.62 m USD2024: EBIT -8.0 m USD20242025: 0.46 m USD2025: EBIT -18 m USD20250.46-18
RevenueOperating profit (EBIT)
Ask Clarifo about Mangoceuticals, Inc

Business

Share of revenue
Compounded men’s wellness products70 %

Custom-compounded prescription products for ED, hair loss, hormone support, and weight loss.

FDA-approved prescription therapy20 %

PRIME by MangoRx, powered by Kyzatrex®, an oral testosterone replacement therapy.

Telemedicine platform services10 %

Online access to licensed healthcare professionals and prescription fulfillment workflow.

Customers

The company sells primarily to adult men seeking discreet, online access to prescription wellness treatments. Its customers are typically patients looking for convenience, privacy, and physician-directed treatment for conditions such as erectile dysfunction, hair loss, low testosterone, and weight management. The platform also depends on prescribers and pharmacy fulfillment partners to convert demand into completed orders.

Men seeking ED treatment

Buy Mango ED products for discreet, prescription-based erectile dysfunction care.

Men with hair-loss concerns

Buy Grow-branded products to address hair-loss treatment needs through telemedicine.

Men with low testosterone or hormone issues

Buy Mojo products or PRIME for testosterone-related therapy and symptom management.

Weight-management patients

Buy Slim products for prescription-based weight-loss support.

Telehealth users

Use the platform to connect with licensed healthcare professionals and obtain prescriptions.

Strategy

Management is focused on aggressive customer acquisition through marketing, platform enhancements, and expansion of its men’s wellness product set. The company also wants to grow organically and through acquisitions in technology, health, and wellness, but execution depends on continued access to capital. Its strategy is built around scaling a digital healthcare brand while broadening the product mix and fulfillment capabilities.

Customer acquisition through marketingShort term

The model depends on generating online demand for prescription products.

Platform and product expansionMedium term

Broader offerings can increase repeat usage and cross-sell across men’s wellness categories.

Acquisition-led growthMedium term

Acquisitions could add products, technology, or distribution, but require funding and integration.

Geography

Mangoceuticals is headquartered in Dallas, Texas and appears to operate primarily in the United States. Its business is tied to U.S. telemedicine, pharmacy fulfillment, and FDA/regulatory requirements, so domestic healthcare rules are a central operating constraint. The company has not disclosed a meaningful country-by-country revenue split in the provided excerpts.

Risks

The company is highly exposed to FDA, telemedicine, and compounding-pharmacy regulation because its products are prescription-based and sold online. It also faces financing risk, since operations and growth plans depend on external capital and management has indicated that future funding could be dilutive. Product concentration, related-party fulfillment, and the replicability of compounded formulas add competitive and execution risk.

Sorted by severity
LowMediumHighLowMediumHighImpact →Likelihood →Capital shortage and dilution1Regulatory delay or restriction2Related-party fulfillment dependence3
Impact is the risk’s severity and likelihood how probable it is over the next few years, both assessed from the company’s reports. Numbers match the list.
  1. Capital shortage and dilutionImpact: HighLikelihood: High

    The company states it may need additional debt or equity financing to fund operations and growth.

    ExposureWorking capitalMarketingAcquisitionsContinued operations
  2. Regulatory delay or restrictionImpact: HighLikelihood: Medium

    The business sells prescription products online and depends on FDA and state healthcare rules.

    ExposureProduct approvalsAdvertising claimsManufacturing inspectionsTelemedicine operations
  3. Related-party fulfillment dependenceImpact: MediumLikelihood: Medium

    All compounded products and Prime orders are fulfilled by Epiq Scripts, a related-party pharmacy.

    ExposureSupply continuityPricingConflicts of interestOperational control
  4. Competitive replication of productsImpact: Medium

    The company notes its compounded formulas are publicly disclosed and can be replicated.

    ExposureBrand differentiationPricing powerCustomer retention
Ask Clarifo about Mangoceuticals, Inc

Accounting

Judgemental items
Revenue recognition for telemedicine and prescription fulfillment

The company sells online healthcare services and prescription products, so timing of delivery and service completion matters.

Impact: Quarterly revenue and deferred revenue balances

Stock-based compensation

The company issued shares for services and compensation, creating non-cash expense and dilution effects.

Impact: Operating expenses and earnings per share

Goodwill and intangible asset impairment

Management explicitly cites impairment testing as a critical estimate.

Impact: Potential non-cash write-downs

Related-party transactions and licensing agreements

Fulfillment and service arrangements with related parties require careful valuation and disclosure.

Impact: Expense recognition, liabilities, and comparability

Similar listed companies

Publicly listed companies with a comparable business focus.

Mannatech, Incorporated

MTEX · Medicinal Chemicals & Botanical Products

Tango Therapeutics, Inc.

TNGX · Pharmaceutical Preparations

Cosmos Health Inc.

COSM · Wholesale-Drugs, Proprietaries & Druggists' Sundries

Evofem Biosciences, Inc.

EVFM · Pharmaceutical Preparations

TherapeuticsMD, Inc.

TXMD · Pharmaceutical Preparations

Monte Rosa Therapeutics, Inc.

GLUE · Biological Products, (No Diagnostic Substances)

Last updated: 24/09/2026